BCLC-B hepatocellular carcinoma treatment or when should the systemic therapy be started

Choice of the optimal therapy for BCLC-B hepatocellular carcinoma (HCC) is a significant clinical problem. Transarterial chemoembolisation (TACE) is considered to be the method of choice as this approach is reported to produce a direct effect and to have a significant survival rate. However, TACE is...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: V. V. Breder, M. U. Pitkevich, E. R. Virshke, L. A. Kostyakova, I. A. Dzhanyan, K. K. Laktionov
Aineistotyyppi: Artigo
Kieli:Russo
Julkaistu: Remedium Group LLC 2018-07-01
Sarja:Медицинский совет
Aiheet:
hepatocellular carcinoma
hcc
transarterial chemoembolization (tace)
sorafenib
regorafenib
bclc
Linkit:https://www.med-sovet.pro/jour/article/view/2529
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia